Published in Proc Natl Acad Sci U S A on November 19, 2009
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology (2013) 1.61
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci (2014) 1.25
A fatty gut feeling. Trends Endocrinol Metab (2013) 1.10
Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol (2011) 1.07
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep (2013) 1.02
Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience (2010) 1.01
Mast cells, glia and neuroinflammation: partners in crime? Immunology (2014) 0.99
Architecture of cannabinoid signaling in mouse retina. J Comp Neurol (2010) 0.99
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain (2012) 0.99
Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. J Neuroinflammation (2012) 0.98
Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem (2010) 0.97
Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci (2012) 0.91
Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol Res (2014) 0.91
β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. ACS Med Chem Lett (2012) 0.91
Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS One (2012) 0.91
Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology (2012) 0.91
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm (2013) 0.90
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. PLoS One (2012) 0.88
An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging (2011) 0.88
A lipid gate for the peripheral control of pain. J Neurosci (2014) 0.88
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB J (2014) 0.87
Generation of N-acylphosphatidylethanolamine by members of the phospholipase A/acyltransferase (PLA/AT) family. J Biol Chem (2012) 0.86
Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol (2014) 0.86
The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesis. Stem Cell Res Ther (2012) 0.85
Proteome alterations in primary human alveolar macrophages in response to influenza A virus infection. J Proteome Res (2012) 0.85
A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chem Biol (2015) 0.83
Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. Structure (2015) 0.83
Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase. J Proteome Res (2012) 0.83
Endocannabinoid signalling in innate and adaptive immunity. Immunology (2015) 0.83
3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration. ChemMedChem (2014) 0.82
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. Eur J Med Chem (2011) 0.82
High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS One (2011) 0.81
Activity-Based Probe for N-Acylethanolamine Acid Amidase. ACS Chem Biol (2015) 0.80
Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats. PLoS One (2015) 0.80
Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS One (2012) 0.80
Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase inhibition. PLoS One (2012) 0.79
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol (2016) 0.79
Site-specific and time-dependent activation of the endocannabinoid system after transection of long-range projections. PLoS One (2012) 0.77
Effects of acute stress on cardiac endocannabinoids, lipogenesis, and inflammation in rats. Psychosom Med (2013) 0.77
Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. J Neuroinflammation (2014) 0.77
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia. Pain (2012) 0.77
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics (2016) 0.76
Dietary non-esterified oleic Acid decreases the jejunal levels of anorectic N-acylethanolamines. PLoS One (2014) 0.76
Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA). ACS Chem Neurosci (2012) 0.76
The anti-inflammatory compound palmitoylethanolamide inhibits prostaglandin and hydroxyeicosatetraenoic acid production by a macrophage cell line. Pharmacol Res Perspect (2017) 0.75
Lipid signaling and fat storage in the dark-eyed junco. Gen Comp Endocrinol (2017) 0.75
Glial Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration. Front Aging Neurosci (2016) 0.75
Palmitoylethanolamide Reduces Neuropsychiatric Behaviors by Restoring Cortical Electrophysiological Activity in a Mouse Model of Mild Traumatic Brain Injury. Front Pharmacol (2017) 0.75
Endogenous N-acyl taurines regulate skin wound healing. Proc Natl Acad Sci U S A (2016) 0.75
Bile Acid Recognition by NAPE-PLD. ACS Chem Biol (2016) 0.75
LPS-induced modules of co-expressed genes in equine peripheral blood mononuclear cells. BMC Genomics (2017) 0.75
Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α. Sci Rep (2015) 0.75
High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. Mol Pain (2016) 0.75
A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. Sci Rep (2017) 0.75
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. BMC Vet Res (2017) 0.75
2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation. Front Pharmacol (2017) 0.75
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Points of control in inflammation. Nature (2002) 10.61
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A (1997) 7.07
Control of pain initiation by endogenous cannabinoids. Nature (1998) 4.73
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature (2008) 3.94
Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov (2008) 3.93
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Structure and function of fatty acid amide hydrolase. Annu Rev Biochem (2005) 3.33
A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature (1995) 3.30
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol (2007) 3.23
Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol (2006) 3.20
Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med (1997) 2.61
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A (2004) 2.23
A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A (2006) 2.08
Can the immune system be harnessed to repair the CNS? Nat Rev Neurosci (2008) 1.83
Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem (2005) 1.83
Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem (1997) 1.72
The search for the palmitoylethanolamide receptor. Life Sci (2005) 1.68
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol (1996) 1.61
Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem (2001) 1.57
Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2008) 1.45
Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol (2008) 1.43
The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers (2007) 1.31
Serine and threonine beta-lactones: a new class of hepatitis A virus 3C cysteine proteinase inhibitors. J Org Chem (2002) 1.25
Prostaglandins, bioassay and inflammation. Br J Pharmacol (2006) 1.24
Factor in arachis oil depressing sensitivity to tuberculin in B.C.G.-infected guineapigs. Lancet (1956) 1.22
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol (2001) 1.17
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA (2007) 1.14
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 1.14
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta (2005) 1.12
Conjugated bile acid hydrolase is a tetrameric N-terminal thiol hydrolase with specific recognition of its cholyl but not of its tauryl product. Biochemistry (2005) 1.12
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 1.12
Autoproteolytic cleavage and activation of human acid ceramidase. J Biol Chem (2008) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
Structural and functional analysis of a conjugated bile salt hydrolase from Bifidobacterium longum reveals an evolutionary relationship with penicillin V acylase. J Biol Chem (2006) 1.04
Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia (2001) 0.98
Tonic inhibition of chemotaxis in human plasma. Proc Natl Acad Sci U S A (2008) 0.98
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem (2008) 0.97
Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARalpha. Lipids (2007) 0.96
Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase. J Med Chem (2003) 0.94
[Activity of some derivatives of palmitoylethanolamide on carragenine-induced edema in the rat paw]. Boll Soc Ital Biol Sper (1968) 0.94
8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ (2000) 0.92
Beta-lactones as a new class of cysteine proteinase inhibitors: inhibition of hepatitis A virus 3C proteinase by N-Cbz-serine beta-lactone. Org Lett (1999) 0.83
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science (2009) 5.35
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci (2010) 2.73
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev (2006) 2.25
A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med (2003) 2.24
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids (2002) 1.98
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 1.96
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab (2010) 1.91
A neuroscientist's guide to lipidomics. Nat Rev Neurosci (2007) 1.87
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron (2003) 1.80
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol (2003) 1.77
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem (2006) 1.71
The search for the palmitoylethanolamide receptor. Life Sci (2005) 1.68
Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol (2005) 1.66
Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med (2008) 1.65
A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol (2007) 1.63
Long-term functional evaluation of the treated kidney in a prospective series of patients who underwent laparoscopic partial nephrectomy for small renal tumors. Eur Urol (2012) 1.63
Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (2009) 1.60
Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev (2005) 1.57
Interleukin-1β causes anxiety by interacting with the endocannabinoid system. J Neurosci (2012) 1.55
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. Pain (2011) 1.55
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol (2007) 1.53
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53